carboxyamido-triazole has been researched along with imatinib mesylate in 4 studies
| Studies (carboxyamido-triazole) | Trials (carboxyamido-triazole) | Recent Studies (post-2010) (carboxyamido-triazole) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 105 | 15 | 22 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | carboxyamido-triazole (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessandro, R; Colomba, P; Corrado, C; De Leo, G; Flugy, AM; Fontana, S; Giordano, M; Kohn, EC; Santoro, A | 1 |
| Ballman, KV; Bot, B; Buckner, JC; DeMatteo, RP; Hillman, SL; Mandrekar, SJ; Nelson, H; Perez, EA; Sargent, DJ | 1 |
| Alessandro, R; Arlinghaus, R; Corrado, C; Flugy, AM; Fontana, S; Iovino, F; Kohn, EC; Leo, GD; Marfia, A; Raimondo, S; Santoro, A; Stassi, G | 1 |
| Alessandro, R; Corrado, C; De Leo, G; Flugy, AM; Guggino, G; Karmali, R; Raimondo, S; Taverna, S | 1 |
4 other study(ies) available for carboxyamido-triazole and imatinib mesylate
| Article | Year |
|---|---|
Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Molecular Probes; Phosphotyrosine; Piperazines; Pyrimidines; ras Proteins; Triazoles | 2008 |
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Piperazines; Placebos; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Oxidation-Reduction; Piperazines; Pyrimidines; Reactive Oxygen Species; Triazoles | 2011 |
Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Exosomes; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Interleukin-8; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neovascularization, Pathologic; Orotic Acid; Phosphorylation; Phosphotyrosine; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger; Triazoles; Xenograft Model Antitumor Assays | 2012 |